New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
13:25 EDTACAD, ACAD, CYTK, CYTK, GILD, GILD, SHPG, SHPG, SNY, SNY, ACOR, ACOR, ALXN, ALXN, FURX, FURX, THLD, THLDCowen to host a conference
33rd Annual Health Care Conference is being held in Boston on March 4-6 with webcasted company presentations to begin on March 4 at 1:30 pm; not all company presentations may be webcasted. Webcast Link
News For ACAD;CYTK;GILD;SHPG;SNY;ACOR;ALXN;FURX;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 14, 2014
14:53 EDTGILD, SNYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
November 13, 2014
13:32 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
07:40 EDTSNYSanofi investor meeting timing tough in light of CEO ouster, Reuters says
Subscribe for More Information
07:10 EDTTHLDSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 12, 2014
08:13 EDTSNY, ACORBoston Biotech to hold a conference
Subscribe for More Information
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
November 11, 2014
16:14 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
10:14 EDTSNYRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
09:13 EDTACADACADIA NDA filing delay minor, says JMP Securities
Subscribe for More Information
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
07:13 EDTACADACADIA filing delay does not impact price target, says Piper Jaffray
Subscribe for More Information
07:07 EDTTHLDThreshold Pharmaceuticals receives FDA fast track designation for TH-302
Threshold Pharmaceuticals announced that the FDA granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, or STS. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may consider a "rolling review" of completed sections of the New Drug Application before the complete application is submitted.
05:26 EDTSNYRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use